Anwendung von Teduglutid bei Kurzdarmsyndrom im Säuglings-, Kindes- und Jugendalter: Positionspapier der Arbeitsgruppe „Chronisches Darmversagen“ der Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE)

Paediatric short bowel syndrome (SBS) with chronic intestinal failure (IF) is a rare, complex and potentially life-threatening condition. The main causes in children are necrotizing enterocolitis, volvulus, congenital malformations, and other enteropathies. The resulting reduced intestinal absorption capacity often requires parenteral nutrition (PN), which is associated with complications such as catheter infections, liver disease, and thrombosis, as well as significant limitations in quality of life. The goal of multidisciplinary treatment is to achieve enteral autonomy, prevent complications, and improve quality of life. With the introduction of the glucagon-like peptide-2 analogue (GLP-2-analogue) teduglutide, an additional therapeutic option is available that can improve fluid and nutrient absorption and reduce the need for parenteral support, up to partial or complete weaning. This position paper summarizes the current evidence on the efficacy and safety of teduglutide in children and provides practice-oriented recommendations from the expert group on the following aspects: Definition of relevant treatment goals (e.g., infusion-free days, enteral autonomy), criteria for indication, classification in the treatment algorithm, requirements for education, care, monitoring, and follow-up. The aim is to create a structured framework for the clinical use of teduglutide in children and adolescents.